AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BCAX · NASDAQ · Biotechnology

Bicara Therapeutics

Developing a bifunctional antibody program for head and neck and other solid tumors.

$23.43

After-hours close+0.02 (+0.06%)

At close$23.42(−5.70%)

Something off on this page? Send us feedback.

Profile

Bicara Therapeutics Inc. Common StockBCAXHealth Care

Develops clinical-stage cancer therapies centered on ficerafusp alfa, an EGFR/TGF-beta antibody program in head and neck cancer. The business is pre-commercial and depends on advancing one lead asset through clinical development, with broader expansion aimed at other solid tumors.

Develops oncology therapies around ficerafusp alfa, a bifunctional EGFR/TGF-beta antibody for head and neck squamous cell carcinoma. Current work is centered on the FORTIFI-HN01 study and on extending the program into other EGFR-expressing solid tumors.

Operates as a clinical-stage company rather than a diversified drug seller. Research and development drive the model, with operations centered in Boston and clinical activity organized around one lead asset, one core disease setting, and a small current workforce.

Execution depends on trial enrollment, readouts, and regulatory interaction, including the FDA Breakthrough Therapy path for the lead regimen in a defined head and neck setting. Commercial preparation is beginning, but the business remains shaped by progress in one program and by combination use with pembrolizumab.

Company facts

CEOClaire Mazumdar

ListedSep 13, 2024

ExchangeNASDAQ

HeadquartersBoston, MA

CountryUnited States

Employees103

CIK0002023658

ISINUS0554771032

Key statistics

Market cap$1.54B

EPS (ttm)−$3.10

P/E (ttm)−7.56

ROE-41.5%

P/B3.40

P/S0.00

Dividend yield—

Beta1.00vs XLV 0.83

Year to date +42.9% · Average volume (30d) 592.9K

Analysts

Price target, next 12 months$35.00+49.4%Median of 9 analysts · vs the Aug 28 close

ConsensusBuy6 of 9 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $23.43

High$42.00+79.3%

Median$35.00+49.4%

Low$20.00−14.6%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 18, 2026	BMO Capital	Initiate	Outperform		$35
Aug 12, 2026	Wedbush	Reiterate	Outperform		$33
Aug 12, 2026	BTIG	Reiterate	Buy	$28	$39
Aug 12, 2026	Mizuho Securities	Target		$18	$20
Aug 12, 2026	Goldman Sachs	Reiterate	Neutral	$18	$20

Earnings

EPS

Estimate−$0.85

ReportedDue Nov 9, 2026

Revenue

Estimate—

ReportedDue Nov 9, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 11, 2026Q2 FY26	−$0.82	−$0.82	0.0%	—	—	—	−14.32%
May 11, 2026Q1 FY26	−$0.64	−$0.93	−45.3%	—	—	—	−2.36%
Mar 26, 2026Q4 FY25	−$0.72	−$0.68	+5.6%	—	—	—	−2.91%
Nov 10, 2025Q3 FY25	−$0.55	−$0.67	−21.8%	—	—	—	+5.74%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$0	$0
Gross profit	$0	$0	$0	$0	$0	$0
Operating income	−$41.8M	−$32.0M	−$40.7M	−$41.1M	−$60.2M	−$60.0M
Net income	−$36.8M	−$27.4M	−$36.3M	−$37.4M	−$56.2M	−$55.4M
Diluted EPS	−$0.68	−$0.50	−$0.67	−$0.68	−$0.93	−$0.82
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—

Fiscal years (4-quarter sums)FY23 $0 · FY24 $0 · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $497.3M · Total debt $1.2M · Total assets $512.2M · Shareholders' equity $468.8M

Dividends

No dividends on record.

Ownership

Institutions 112.11%Insiders 8.12%

A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.

Shares outstanding 65.70M · Float 36.30M · 55.3% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Peter Kolchinsky	7.28M	11.50%	13D	Mar 2, 2026
Ra Capital Management, L.P.	7.26M	11.04%	13F	Aug 14, 2026
T. Rowe Price Investment Management, Inc.	6.34M	9.65%	13F	Aug 14, 2026
Siren, L.L.C.	5.60M	8.53%	13F	Aug 13, 2026
Vestal Point Capital, LP	5.25M	7.99%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 10, 2026	Ryan Cohlhepp	director, officer: President and COO	−18,750	$27.98
Aug 10, 2026	Claire Mazumdar	director, officer: Chief Executive Officer	−10,000	$27.98
Aug 10, 2026	Ivan Hyep	officer: Chief Financial Officer	−12,500	$27.97
Jul 10, 2026	Claire Mazumdar	director, officer: Chief Executive Officer	−10,000	$28.42
Jul 8, 2026	Ivan Hyep	officer: Chief Financial Officer	−28,000	$28.85